항체-약물 접합체(ADC) 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Antibody Drug Conjugates (ADC) Market was valued at USD 16.9 billion in 2025 and is estimated to grow at a CAGR of 11.2% to reach USD 48.1 billion by 2035.

The market expansion is supported by a growing clinical preference for precision oncology treatments that offer improved tumor targeting and reduced systemic toxicity compared to conventional chemotherapy. ADCs are increasingly positioned as a differentiated therapeutic class, where the antibody component enables selective binding to tumor-associated antigens while the conjugated payload delivers localized cytotoxic activity at effective therapeutic concentrations. This dual mechanism continues to reshape treatment paradigms across multiple oncology indications, with rising integration into standard-of-care protocols globally. The market is further strengthened by expanding biomarker-driven patient identification, improved linker chemistry technologies, and broader clinical validation across earlier and later lines of therapy. Increasing adoption in both developed and emerging healthcare systems is reinforcing long-term commercial scalability across the ADC landscape.

Enhertu (trastuzumab deruxtecan), segment held a 29.5% share in 2025 and is projected to grow at a CAGR of 11.3% through 2035. The therapy utilizes Daiichi Sankyo's DXd platform, which incorporates a cleavable peptide linker connected to a topoisomerase I inhibitor payload, engineered to achieve a high drug-to-antibody ratio of around 8, enhancing intracellular drug delivery efficiency and therapeutic potency across tumor cells expressing low antigen levels.

The hospitals and oncology clinics segment accounted for 57.4% share in 2025 and is expected to grow at a CAGR of 11.1% through 2035. The dominance of this segment is linked to the intravenous administration requirement of all approved ADC therapies, which necessitates controlled clinical environments with specialized oncology staff. Treatment delivery is concentrated in hospital-based infusion units where patient monitoring, adverse reaction management, and regulatory compliance protocols for high-potency biologics are strictly maintained throughout therapy cycles.

North America Antibody Drug Conjugates (ADC) Market captured 41.9% share in 2025 and is projected to grow at a CAGR of 10.8% through 2035, making it the most developed regional market. The United States leads regional demand, supported by an advanced regulatory ecosystem that enables accelerated drug approvals and early commercialization pathways, allowing innovative oncology biologics to reach patients more rapidly compared to other global markets.

Key players involved in the Antibody Drug Conjugates (ADC) Market are AbbVie, ADC Therapeutics, Astellas Pharma, AstraZeneca, Daiichi Sankyo, Gilead Sciences, GSK, Pfizer, Roche, and Takeda Pharmaceutical are among the leading companies shaping the antibody drug conjugates market. Key strategies adopted by companies in the ADC market focus on advancing next-generation linker and payload technologies to improve tumor selectivity and reduce off-target toxicity. Firms are heavily investing in clinical pipeline expansion across multiple oncology indications to strengthen lifecycle value and broaden label opportunities. Strategic collaborations between biopharma companies are accelerating R&D capabilities and enabling co-development of novel ADC candidates. Companies are also pursuing biomarker-driven patient stratification approaches to improve clinical trial success rates and treatment precision. In addition, acquisitions and licensing agreements are being used to access innovative ADC platforms and diversify portfolios. Manufacturing scale-up investments are strengthening commercial supply reliability, while geographic expansion into emerging healthcare markets is supporting wider patient access and long-term revenue growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis
  • 2.1.1 Business trends
  • 2.1.2 Product type trends
  • 2.1.3 Technology trends
  • 2.1.4 Application trends
  • 2.1.5 Target type trends
  • 2.1.6 Mechanism of action trends
  • 2.1.7 End use trends
  • 2.1.8 Regional trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer
    • 3.2.1.2 Growing demand for antibody-based cancer therapies
    • 3.2.1.3 Increasing advancements in antibody technology
    • 3.2.1.4 Expanding approval of ADCs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development and manufacturing costs
    • 3.2.2.2 Safety and toxicity concerns associated with ADCs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Shift toward solid tumor ADCs with higher unmet needs.
    • 3.2.3.2 Adoption of next-generation ADC technologies
• 3.3 Growth potential analysis
• 3.4 Technology and innovation landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Pipeline analysis
• 3.6 Regulatory landscape (Driven by primary research)
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 MEA
• 3.7 Commercial CDMO landscape and supply chain architecture
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Future market trends
• 3.11 Impact of AI and Generative AI on the market (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Enhertu
• 5.3 Kadcyla
• 5.4 Adcetris
• 5.5 Padcev
• 5.6 Trodelvy
• 5.7 Polivy
• 5.8 Other product types

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Cleavable linker
• 6.3 Non-cleavable linker

Chapter 7 Market Estimates and Forecast, By Drug Type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Small-molecule drugs
• 7.3 Large-molecule drugs

Chapter 8 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Breast cancer
• 8.3 Blood cancer
  • 8.3.1 Lymphoma
  • 8.3.2 Leukemia
  • 8.3.3 Multiple myeloma
• 8.4 Urothelial cancer & bladder cancer
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Target Type, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 HER2
• 9.3 CD30
• 9.4 CD22
• 9.5 Other target types

Chapter 10 Market Estimates and Forecast, By Mechanism of Action, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 Microtubule inhibitors
• 10.3 Topoisomerase I inhibitors
• 10.4 DNA-damaging agents
• 10.5 Others

Chapter 11 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 11.1 Key trends
• 11.2 Hospitals and clinics
• 11.3 Oncology centers
• 11.4 Other end users

Chapter 12 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 France
  • 12.3.3 UK
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Netherlands
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 Japan
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 South Korea
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Argentina
• 12.6 Middle East & Africa
  • 12.6.1 Saudi Arabia
  • 12.6.2 South Africa
  • 12.6.3 UAE

Chapter 13 Company Profiles

• 13.1 AbbVie
• 13.2 ADC Therapeutics
• 13.3 Astellas Pharma
• 13.4 AstraZeneca
• 13.5 Daiichi Sankyo
• 13.6 Gilead
• 13.7 GSK
• 13.8 Pfizer
• 13.9 Roche
• 13.10 Takeda Pharmaceutical